Phil Nadeau Affirms Buy Rating on Kura Oncology Thanks to Promising Clinical Trials and Robust Financial Position
TD Cowen analyst Phil Nadeau has maintained their bullish stance on KURA stock, giving a Buy rating yesterday. Phil Nadeau has given his Buy ...
Business Insider24d
Optimistic Buy Rating for Kura Oncology Driven by Promising Ziftomenib Performance
Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA. Read More on KURA: Kura Oncology NewsMORE Related Stocks Indices Commodities Currencies ...